Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-4 and breast cancer.

S Nagai1, M Toi

  • 1Department of Surgery, Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan.

Breast Cancer (Tokyo, Japan)
|October 13, 2000
PubMed
Summary

Interleukin-4 (IL-4) exhibits anti-tumor properties against breast cancer by inducing apoptosis and regulating estrogen synthesis. This cytokine is a key factor in human breast cancer progression and immune responses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up<sup>†</sup>.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727].

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.

ESMO open·2024
Same author

Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B.

ESMO open·2024
Same author

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Area of Science:

  • Immunology
  • Oncology
  • Endocrinology

Background:

  • Interleukin-4 (IL-4) is a cytokine produced by T lymphocytes with diverse cellular targets.
  • Initially identified as a B cell growth factor, IL-4 demonstrates significant anti-tumor activity, particularly in breast cancer.
  • IL-4 influences key enzymes involved in estrogen synthesis, such as 17beta-HSD and 3beta-HSD.

Purpose of the Study:

  • To elucidate the multifaceted role of IL-4 in human breast cancer.
  • To investigate IL-4's impact on apoptosis and estrogen synthesis pathways in breast cancer cells.

Main Methods:

  • Analysis of IL-4's effects on cultured breast cancer cells.
  • Examination of IL-4's regulatory role in estrogen synthesis enzymes (17beta-HSD and 3beta-HSD).

Main Results:

  • IL-4 induces apoptosis in cultured breast cancer cells.
  • IL-4 plays a crucial role in regulating estrogen synthesis enzymes.
  • IL-4 demonstrates potent anti-tumor activity against various tumors, including breast cancer.

Conclusions:

  • IL-4 is a critical factor in human breast cancer, influencing both immune responses and tumor cell growth.
  • IL-4's ability to induce apoptosis and modulate estrogen synthesis highlights its therapeutic potential in breast cancer treatment.

Related Experiment Videos